BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
35 hedge funds and large institutions have $7.11M invested in BRAINSTORM CELL THERAPUTC in 2017 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 4 reducing their positions, and 4 closing their positions.
225% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 4
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
9% more funds holding
Funds holding: 32 → 35 (+3)
6% more capital invested
Capital invested by funds: $6.72M → $7.11M (+$395K)
0.07% more ownership
Funds ownership: 0.58% → 0.64% (+0.07%)
41% less call options, than puts
Call options by funds: $80K | Put options by funds: $135K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$365K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$302K |
| 3 |
CC
Clearline Capital
New York
|
+$212K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$70.7K |
| 5 |
IWM
IHT Wealth Management
Chicago,
Illinois
|
+$35.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
-$206K |
| 2 |
JP Morgan Chase
New York
|
-$68K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$57K |
| 4 |
VF
Virtu Financial
New York
|
-$52K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$8.55K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AG
26
Advisor Group
Phoenix,
Arizona
| $10K | +$2.03K | +34 | +26% |
|
27
Bank of Montreal
Toronto,
Ontario, Canada
| $8K | +$7.95K | +133 | New |
|
|
28
UBS Group
Zurich,
Switzerland
| $7K | -$8.55K | -143 | -53% |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $6K | -$1.14K | -19 | -16% |
|
30
Simplex Trading
Chicago,
Illinois
| $4K | +$4.31K | +72 | New |
|
|
ASN
31
Advisory Services Network
Atlanta,
Georgia
| $2K | – | – | – |
|
|
RE
32
RBC Europe
London,
United Kingdom
| $1.83K | – | – | – |
|
33
Citigroup
New York
| $1K | – | – | – |
|
34
US Bancorp
Minneapolis,
Minnesota
| $1K | – | – | – |
|
|
MCM
35
Monument Capital Management
Alexandria,
Virginia
| $1K | +$1.32K | +22 | New |
|
|
36
CIBC Private Wealth Group
Atlanta,
Georgia
| – | -$206K | -3,333 | Closed |
|
|
37
JP Morgan Chase
New York
| – | -$68K | -1,106 | Closed |
|
|
OAM
38
Oxford Asset Management
Oxford,
United Kingdom
| – | -$57K | -925 | Closed |
|
|
VF
39
Virtu Financial
New York
| – | -$52K | -838 | Closed |
|
BCLI Hedge Fund Activity: Q4 2017 in Review
35 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q4 2017, worth a combined $7.11M — up 5.9% from $6.72M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BCLI positions and 4 closed out — a net gain of 3 holders — while 13 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $365K. The largest seller was CIBC Private Wealth Group, exiting entirely with an estimated $206K sold.
- 35 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q4 2017, up from 32 in Q3 2017.
- Funds reported $7.11M of BRAINSTORM CELL THERAPUTC stock for Q4 2017, up 5.9% quarter-over-quarter.
- 7 funds opened new BRAINSTORM CELL THERAPUTC positions in Q4 2017 and 4 closed out, a net change of +3 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q4 2017 was Renaissance Technologies, an estimated $365K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q4 2017 was CIBC Private Wealth Group, an estimated $206K sold.
Based on aggregated 13F filings for Q4 2017.